Elmiron litigation
Lawsuits allege that long-term use of Elmiron, the only oral drug approved for interstitial cystitis, causes a distinctive and permanent retinal injury.
Accepting cases
What the lawsuits allege
Beginning in 2018, ophthalmologists described a previously unrecognized pattern of retinal damage in long-term Elmiron users. The litigation alleges the manufacturer possessed decades of signals connecting pentosan polysulfate to eye injury yet did not warn patients until 2020, after many had taken the drug daily for years.
Injuries named in the litigation
- Pigmentary maculopathy
- Blurred and distorted central vision
- Difficulty adapting to dim light
- Progressive vision loss after stopping the drug
Who may qualify
If you took Elmiron for two years or longer and were diagnosed with maculopathy, macular degeneration, or unexplained retinal injury, you may have a claim. The review is free and confidential, and we will give you an honest answer either way. You pay attorney's fees only if we recover for you.
Call (888) 391‑1315 or use the form for a free, confidential review. You pay attorney's fees only if we recover for you.